- Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
- Addex Announces Participation in the H.C. Wainwright Global Investment Conference
- Addex Announces Participation in the 22nd Bio€quity Europe Conference
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Reports Q1 2022 Financial Results
- Addex to Present at the Swiss Biotech Day 2022
- Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
- Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
- Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
- Addex Convenes Annual General Meeting 2022
More ▼
Key statistics
52-week range
Markit short selling activity
Open | 0.590 |
---|---|
High | 0.590 |
Low | 0.551 |
Bid | 0.562 |
Offer | 0.61 |
Previous close | 0.619 |
Average volume | 30.90k |
---|---|
Shares outstanding | 65.27m |
Free float | 64.89m |
P/E (TTM) | -- |
Market cap | 38.18m CHF |
EPS (TTM) | -0.5203 CHF |
Data delayed at least 15 minutes, as of May 27 2022 16:31 BST.
More ▼